Interleukin-2 mutant proteins for the proliferation of regulatory T cells
IL-2 mutein proteins fused with the Fc region of antibodies address the challenge of selectively stimulating Tregs by extending serum half-life and reducing immunogenicity, resulting in improved therapeutic efficacy and safety for autoimmune and inflammatory diseases.
JP7649349B2Active Publication Date: 2025-03-19AMGEN INC
10 Cites 0 Cited by
Patent Information
- Application Number
- JP2023106755
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-06-29
- Publication Date
- 2025-03-19
- Estimated Expiration
- 2036-05-04
AI Technical Summary
Technical Problem
Existing IL-2 therapies face challenges in selectively stimulating regulatory T cells (Tregs) while minimizing immune responses and improving pharmacokinetics for effective therapeutic outcomes in autoimmune and inflammatory diseases.
Method used
Development of IL-2 mutein proteins fused with the Fc region of antibodies, specifically engineered to have an extended serum half-life, reduced immunogenicity, and enhanced stability, which preferentially stimulate Tregs over other T cells.
Benefits of technology
The IL-2 mutein Fc fusion proteins achieve selective proliferation and activation of Tregs, reducing the frequency of dosing and minimizing adverse immune responses, thereby providing a more effective and safer therapeutic approach for autoimmune and inflammatory diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
To provide IL-2 muteins that have optimal attributes for human therapeutics.SOLUTION: A human interleukin-2 (IL-2) mutein comprises an amino acid sequence that is at least 90% identical to a specific amino acid sequence, and preferentially stimulates T-regulatory cells relative to other T cells or NK cells, both in in-vitro assays and in humanized mice (NSG mice reconstituted with CD34+ hematopoietic stem cells).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art